Evidence map›Paper›PMID 37198628›Full record

ArticleMicrobial cell factories2023

Improved biosynthesis of heme in Bacillus subtilis through metabolic engineering assisted fed-batch fermentation.

Shaomei Yang, Anlong Wang, Jiachang Li, Yunhang Shao, Fengjie Sun, Shucheng Li, Kai Cao, Hongliang Liu, Peng Xiong, Zhengquan Gao

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Metabolic engineering ofProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Recent advances in microbial synthesis of free heme.Applied microbiology and biotechnology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Multi-modular metabolic engineering of heme synthesis inSynthetic and systems biotechnology · 2024
    Article
  10. Improving Surfactin Production inMicroorganisms · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shaomei YangSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Anlong WangSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Jiachang LiSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Yunhang ShaoSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Fengjie SunSchool of Science and Technology, Georgia Gwinnett College, Lawrenceville, GA, 30043, USA.
Shucheng LiSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Kai CaoSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Hongliang LiuSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China.
Peng XiongSchool of Life Sciences and Medicine, Shandong University of Technology, 266 Xincun West Road, Zibo, 255000, China. xiongp@sdut.edu.cn.
Zhengquan GaoSchool of Pharmacy, Binzhou Medical University, 346 Guanhai Road, Yantai, 256603, China. gaozhengquan@bzmc.edu.cn.
Shandong University of Technology · CNBinzhou University · CNGwinnett College · US

Funding

National Natural Science Foundation of China 31972815National Natural Science Foundation of China 42177403Natural Science Foundation of Shandong Province ZR2019ZD17Natural Science Foundation of Shandong Province ZR2020MD121
6 · The paper itself

Abstract

backgroundHeme is an iron/porphyrin complex compound, widely used in the health care, food, and pharmaceutical industries. It is more advantageous and attractive to develop microbial cell factories to produce heme by fermentation, with lower production costs and environmentally more friendly procedures than those of the traditional extraction based on animal blood. In this study, Bacillus subtilis, a typical industrial model microorganism of food safety grade, was used for the first time as the host to synthesize heme.

resultsThe heme biosynthetic pathway was engineered as four modules, the endogenous C5 pathway, the heterologous C4 pathway, the uroporphyrinogen (urogen) III synthesis pathway, and the downstream synthesis pathway. Knockout of hemX encoding the negative effector of the concentration of HemA, overexpression of hemA encoding glutamyl-tRNA reductase, and knockout of rocG encoding the major glutamate dehydrogenase in the C5 pathway, resulted in an increase of 427% in heme production. Introduction of the heterologous C4 pathway showed a negligible effect on heme biosynthesis. Overexpression of hemCDB, which encoded hydroxymethylbilane synthase, urogen III synthase, and porphobilinogen synthase participating in the urogen III synthesis pathway, increased heme production by 39%. Knockouts of uroporphyrinogen methyltransferase gene nasF and both heme monooxygenase genes hmoA and hmoB in the downstream synthesis pathway increased heme production by 52%. The engineered B. subtilis produced 248.26 ± 6.97 mg/L of total heme with 221.83 ± 4.71 mg/L of extracellular heme during the fed-batch fermentation in 10 L fermenter.

conclusionsStrengthening endogenous C5 pathway, urogen III synthesis pathway and downstream synthesis pathway promoted the biosynthesis of heme in B. subtilis. The engineered B. subtilis strain has great potential as a microbial cell factory for efficient industrial heme production.

Indexed as

Bacillus subtilisHemeFermentationMetabolic EngineeringUroporphyrinogensHemeUroporphyrinogensBacillus subtilisDownstream synthesis pathwayEndogenous C5 pathwayHeme biosynthesisUroporphyrinogen III synthesis pathway

Identifiers

PMID37198628
PMCPMC10193802
OpenAlexW4377010451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.